Paroxetine {(-)-(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine]} is an SSRI antidepressant. Marketing of the drug began in 1992 by the pharmaceutical company SmithKlineBeecham. The effectiveness of paroxetine in major depressive disorder has been proven by six placebo-controlled clinical trials [1, 2]. Since in medicinal products beside (-)-trans-paroxetine  its probably inactive enantiomer [3] may be present, appropriate analytical procedures are necessary to determine a content of the second enantiomer (which in best case could be devoid of any pharmacological activity but very often may be responsible for serious adverse effects).

Here we report validated analytical procedure enabling determination of (+/-)-trans-paroxetine  in medicinal products containing (+)-trans-paroxetine as a main active ingredient with the aid silica-bonded ovomucoin protein  chiral stationary phase. Validation included: specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), assay, precision and recovery.

1. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.  J. Affect. Disord. 58, 19-36 (2000).
2.  Montgomery S.A. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. International. Clin. Psychopharmacol. 16, 169-78 (2001).
3. Segura M., Roura L., de la Torre R., Joglar J.; Synthesis of the major metabolites
   of paroxetine, Bioorg. Chem. 31, 248-258 (2003).

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/25493 must be provided.

1. Serotonin transporter inhibitors inducing hypothermia at mice
2. New analog of sulforaphane: 2-oxoheptyl isothiocyanate  as a compound with selective effect on the normal and colon cancer cells.
3. Ligand-directed receptor trafficking
4. Fullerenes as the carriers of compounds with amide bond
5. Comparison of combined effects of 5-fluorouracil and allysin after concurrent treatment in colon and breast cancer cell lines
6. Sulforaphane modulates MRP expression and activity in Caco-2 cells
7. Molecular properties of antifungal agents – Impact on bioavailability – The Biopharmaceutics Classification System
8. Proapoptotic effects of new pentabromobenzylisothioureas and CK2 inhibitor in prostate adenocarcinoma cell line
9. The combined effect of 5-fluorouracil and sulforaphane in prostate cancer cell line
10. Formation of Caco-2 monolayer - model for the prediction of intestinal drug absorption; method validation.
11. On tautomerism of the pyridodiazepines. A DFT study.
12. Application of amylose tris(3,5dimethylphenyl- carbamate) chiral stationary phase for the determination of paroxetine, clinically used psychotropic drug
13. Examination of optical isomerism - compounds of antihypertensive effects.
14. Molecular properties of active ingredients Impact on bioavailability The biopharmaceutics classification system
15. Homology modeling of G-protein coupled receptors
16. Direct enantiomeric resolution of tamsulosin, clinically used chiral O-phenylethanolamine derivative with α₁-blocking activity
17. Application of carbohydrate based chiral stationary phase for resolution of  fenoterol, clinically used chiral drug
18. Cyclohexaglycine as a potential ionophore
19. Molecular properties impact on bioavailability of imidazole antifungal agents.
20. Identification of Novel 5-HT₇R Ligands via Multistep Virtual Screening of Commercially Available Compounds Databases
21. Alkyl-nitroquipazine derivatives as serotonin transporter and 5-HT_1A receptor ligands
22. CHO cell line with stable expression of the HTRA1 gene as a tool for studying functional activity of 5-HT_1A receptor ligands
23. Synthesis and proapoptotic properties of new casein kinase II inhibitors
24. Determination of the enantiomeric purity of epinephrine in pharmaceutical preparations
25. Determination of the enantiomeric purity of norepinephrine in pharmaceutical preparations
26. Crystal structure of β-adrenergic receptor as a new template in homology modeling of GPCR. Application to serotonin 5-HT_1A and 5-HT₇ receptors
27. Comparison of properties of cyclic and linear glycine derived structures and their phosphorus analogues - theoretical studies
28. Molecular Properties Relevant to Bioavailability of Tioconazole  and its Derivatives
29. The ligand binding to the serotonin transporter
30. MOLECULAR PROPERTIES OF SULCONAZOLE AND ECONAZOLE RELEVANT TO BIOAVAILABILITY
31. MOLECULAR DETERMINANTS FOR METABOLIC STABILITY OF NICOTINIC AND PICOLINIC ACID DERIVATIVES
32. ANALYTICAL DETERMINATION OF HOMOCYSTEINE AND RELATED AMINOTHIOLS IN HUMAN PLASMA BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH UV DETECTION
33. SYNTHESIS AND HYPOLIPIDEMIC ACTIVITY OF ASARONE ANALOGS IN MALE AND FEMALE RATS
34. SYNTHESIS AND AFFINITY FOR SEROTONIN RECEPTOR 5HT_1A AND SEROTONIN TRANSPORTER OF SOME 6-NITROQUIPAZINE ANALOGUES.
35. MOBILE PHASE INFLUENCE ON CHROMATOGRAPHIC BEHAVIOUR OF SOME 1,4-DISUBSTITUTED PIPERAZINES
36. DETERMINATION OF SELECTED MEDICINES REDUCING THE LEVEL OF CHOLESTEROL BY CHROMATOGRAPHIC METHODS.
37. IDENTIFICATION AND DETERMINATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS WITH DENSITOMETRIC METHOD
38. ENANTIOSELECTIVITIES OF SOME 1,4-DISUBSTITUTED PIPERAZINES ON AMYLOSE CARBAMATE